Sign inJoin waitlistJoin the waitlist

Yasmin Abaza

Assistant Professor · Feinberg School of Medicine

Credentials: · · · · · · · ·

History

Feinberg School of Medicine
Present

UCLA David Geffen School of Medicine/UCLA Medical Center
Until 2020
University of Texas Health Science Center at Houston/M D Anderson Cancer Center
Until 2017
AdventHealth Orlando
Until 2015
University of Alexandria Medical School
2009

Research

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
Blood · 2017 · First of 28 authors · 221 citations
Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology · 2017 · 98 citations
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes
Cancer · 2017 · 90 citations

RS
Rory Shallis
18 papers
Anand Patel
16 papers
Talha Badar
16 papers
Jessica Altman
14 papers
Jan Bewersdorf
11 papers · 8 as a fellow
Mark Litzow
11 papers
Amer Zeidan
10 papers
Ehab Atallah
10 papers
Vamsi Kota
10 papers
Guillermo Garcia-Manero
9 papers
Madina Sukhanova
9 papers
AG
Aaron Goldberg
8 papers

Clinical trials

Luspatercept + Darbepoetin in MDS
Site PI · Recruiting · Phase 2
Yale University
2025–2030
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
Site PI · Unknown · Phase 1, Phase 2
BioSight Ltd.
2022–2025